Pfizer teamed with researchers from the University of Texas Medical Branch in Galveston for lab tests to see if the mutation affected its vaccines capability to do so.They utilized blood samples from 20 people who received the vaccine, made by Pfizer and its German partner BioNTech, throughout a large study of the shots. Antibodies from those vaccine recipients successfully fended off the virus in lab meals, according to the study posted late Thursday on an online website for researchers.The study is initial and has not yet been evaluated by experts, a key step for medical research.But “it was a very comforting finding that at least this anomaly, which was one of the ones individuals are most worried about, does not seem to be an issue” for the vaccine, stated Pfizer chief clinical officer Dr. Philip Dormitzer.Viruses continuously go through minor changes as they spread from individual to individual. Researchers around the world are conducting research with various vaccines to find out.Dormitzer said if the infection eventually mutates enough that the vaccine needs adjusting– much like influenza shots are adjusted most years– that tweaking the dish would not be challenging for his companys shot and similar ones.
- Pfizer vaccine appears effective against rapidly spreading coronavirus variants – CNET
- Los Angeles County Covid-19 deaths in a day equals citys homicide deaths in a year, mayor says – CNN